Another Drug Approved for Treating Chronic Hepatitis C

Sovaldi is the third drug with breakthrough therapy designation to receive FDA's approval.

The U.S. Food and Drug Administration on Dec. 6 approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus infection, stating in a news release that it is "the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon."

"Today's approval represents a significant shift in the treatment paradigm for some patients with chronic hepatitis C," said Dr. Edward Cox, M.D., director of the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research. The agency had approved Olysio (simeprevir) on Nov. 22.

Sovaldi is marketed by Gilead, based in Foster City, Calif.

Bulwark FR Quiz

OH&S Digital Edition

  • OHS Magazine Digital Edition - September 2020

    September 2020

    Featuring:

    • WINTER HAZARDS
      Winter Hazards Preparation Should Kick Off in the Fall Months
    • OIL & GAS
      How Safety Has Become a Priority for the Oil Sector
    • COMBUSTIBLE DUST
      Protecting the Plant from Catastrophic Combustible Dust Explosions
    • FACILITY SAFETY
      Empowering Workers in an Uncertain World
    View This Issue